American Century Companies Inc. Boosts Stock Position in Relx Plc $RELX

Key Points

• American Century Companies Inc. increased its holdings in RELX PLC by 4.0% in the first quarter, now owning 421,270 shares valued at approximately $21.24 million.
• Wall Street analysts have upgraded RELX from a "hold" to a "buy" rating, with one analyst rating it as a Strong Buy and an average rating of "Buy".
• RELX announced a semi-annual dividend of $0.2634 per share, reflecting a yield of 170.0%, with a dividend payout ratio of 28.49%.

American Century Companies Inc. boosted its position in shares of Relx Plc (NYSE:RELX - Free Report) by 4.0% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 421,270 shares of the technology company's stock after acquiring an additional 16,170 shares during the period. American Century Companies Inc.'s holdings in Relx were worth $21,236,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Bleakley Financial Group LLC raised its stake in Relx by 1.5% during the 1st quarter. Bleakley Financial Group LLC now owns 14,147 shares of the technology company's stock worth $713,000 after acquiring an additional 207 shares during the period. Cynosure Group LLC raised its stake in Relx by 3.5% during the 1st quarter. Cynosure Group LLC now owns 6,951 shares of the technology company's stock worth $350,000 after acquiring an additional 236 shares during the period. Bridgewater Advisors Inc. raised its stake in Relx by 2.1% during the 1st quarter. Bridgewater Advisors Inc. now owns 11,463 shares of the technology company's stock worth $617,000 after acquiring an additional 238 shares during the period. Kovitz Investment Group Partners LLC raised its stake in Relx by 3.4% during the 4th quarter. Kovitz Investment Group Partners LLC now owns 8,159 shares of the technology company's stock worth $371,000 after acquiring an additional 267 shares during the period. Finally, Ascent Group LLC raised its stake in Relx by 2.0% during the 4th quarter. Ascent Group LLC now owns 14,024 shares of the technology company's stock worth $637,000 after acquiring an additional 277 shares during the period. Institutional investors own 15.02% of the company's stock.

Relx Price Performance

Shares of Relx stock traded down $0.43 on Friday, hitting $46.54. 341,934 shares of the company traded hands, compared to its average volume of 886,974. The stock has a market capitalization of $85.37 billion, a P/E ratio of 25.02, a price-to-earnings-growth ratio of 3.12 and a beta of 0.88. The company has a debt-to-equity ratio of 2.55, a quick ratio of 0.42 and a current ratio of 0.47. Relx Plc has a 52 week low of $44.19 and a 52 week high of $56.33. The business has a 50-day simple moving average of $51.29 and a 200 day simple moving average of $51.41.

Relx Cuts Dividend

The firm also recently announced a semi-annual dividend, which will be paid on Tuesday, September 16th. Investors of record on Friday, August 8th will be issued a $0.2634 dividend. The ex-dividend date of this dividend is Friday, August 8th. This represents a dividend yield of 170.0%. Relx's dividend payout ratio (DPR) is 28.49%.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded shares of Relx from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. One investment analyst has rated the stock with a Strong Buy rating and four have issued a Buy rating to the company's stock. According to MarketBeat.com, Relx currently has a consensus rating of "Buy".

Relx Company Profile

RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity.